HIMS Stock Forecast & Price Target

Hims & Hers Health is a rapidly growing telehealth company that connects patients and healthcare providers for personalized treatments. Their renewed partnership with Novo Nordisk and expansion into the GLP-1 market, along with solid revenue and subscriber growth, present a strong opportunity for long-term gains. While near-term margin challenges may be a concern, the potential upside from this strategic collaboration is significant. Additionally, Hims & Hers faces competition from both established healthcare giants and nimble, venture-backed startups, but their solid brand and innovative telemedicine platform give them a competitive edge in this crowded market.

Hims & Hers Health is facing challenges with declining average monthly revenue per subscriber and slowing subscriber growth, particularly with the shift in their U.S. weight loss offering and increased investment in scaling infrastructure. Despite increasing revenue guidance for FY26, adjusted EBITDA guidance was revised lower due to these challenges. However, the long-term potential of partnerships with companies like Novo Nordisk and Hims & Hers' focus on expanding globally and into new specialties could drive incremental growth. Tighter regulation around their pharmaceutical compounding business also poses a risk to their business model, and the success and profitability of their DTC approach hinges on maintaining favorable marketing yields and unit economics.